



Attorney Docket No. 701826-055820-RCE

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. 09/719,870
Applicant: Masad J. Damha et al.
Filed: April 12, 2001
For: ANTISENSE OLIGONUCLEOTIDE CONSTRUCTS BASED ON β -ARABINOFURANOSE AND ITS ANALOGUES

Confirmation No.: 5859
TC/A.U.: 1635
Examiner: Janet L. Epps-Ford
Customer No.: 50828

**RESPONSE UNDER
37 C.F.R. SECTION 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP
1635**

CERTIFICATE OF MAILING

I hereby certify that this correspondence:

1. Transmittal Form (1 pg.);
2. Amendment (9 pp.);
3. Return Receipt Postcard;

is on the date shown below being:

MAILING

X deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to MAIL STOP AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Date: December 15, 2005

FACSIMILE

transmitted by facsimile to the Patent and Trademark Office.


Signature

Nicole M. Aguirre
(type or print name of person certifying)



AP
BFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/719,870
	Filing Date	April 12, 2001
	First Named Inventor	Masad J. Damha
	Art Unit	1635
	Examiner Name	Janet L. Epps Ford
	Attorney Docket Number	701826-055820- RCE
Total Number of Pages in This Submission		

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input checked="" type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Certificate of Mailing and Return Receipt Postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	Confirmation No. 5859	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Customer No. 50828	
	The Commissioner is authorized to charge fee deficiencies or credit overpayments associated with this submission to the NIXON PEABODY LLP Deposit Account No. 50-0850.	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	NIXON PEABODY LLP	
Signature		
Printed name	David S. Resnick	
Date	12/15/05	Reg. No. 34,235

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:		
Signature		
Typed or printed name	Nicole M. Aguirre	Date 12/15/05

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Attorney Docket No. 701826-055820-RCE

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. 09/719,870
Applicant: Masad J. Damha et al.
Filed: April 12, 2001
For: ANTISENSE OLIGONUCLEOTIDE CONSTRUCTS BASED ON β -ARABINOFURANOSE AND ITS ANALOGUES

Confirmation No.: 5859
TC/A.U.: 1635
Examiner: Janet L. Epps-Ford

Customer No.: 50828

CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to MAIL AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Date 12/15/05

Nicole M. Aguirre
(type or print name of person mailing paper)

Nicole M. Aguirre
Signature of person mailing paper

MAIL STOP AF
The Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

**RESPONSE UNDER
37 C.F.R. SECTION 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP
1635**

AMENDMENT

Sir:

This communication is responsive to the Office Action dated September 26, 2005, a response to which is due on or before December 26, 2005. Please amend the above-identified patent application as follows:

Amendments to the claims are reflected in the listing of claims which begins on page 2 of this paper.